Based on our previous studies, we identified anti-IL-7Rα mAbs as an interesting candidate for combination therapy: IL-7Rα blockade prevents and reverses T1D by targeting IL-7-dependent effector/memory T cells but long-term administration is required to achieve this effect [1, 2, 28, 29]. This evidence concerns the gene IL7R and type 1 diabetes mellitus.